Hepatitis C in 6,865 patients 65 yr or older: A severe and neglected curable diseas?

American Journal of Gastroenterology

Volumn 101, Issue 6, 2006, Pages 1260-1267

  Thabut, Dominique ^a,b   Le Calvez, Sophie ^a   Thibault, Vincent ^a   Massard, Julien ^a   Munteanu, Mona ^a   Di Martino, Vincent ^a   Ratziu, Vlad ^a   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Service d'Hépato Gastroentérologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; DEVICE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; INFECTION RISK; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; BIOPSY; CHI-SQUARE DISTRIBUTION; FEMALE; FRANCE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; RETROSPECTIVE STUDIES; RIBAVIRIN; SEVERITY OF ILLNESS INDEX;

EID: 33744779670     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00556.x     Document Type: Article

References (31)

1. Tong MJ el-Farra NS Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995 332 : 1463 6.
2. Poynard T Bedossa P Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997 349 : 825 32.
3. Poynard T Ratziu V Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001 34 : 730 9.
4. Manns MP McHutchison JG Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
5. Fried MW Shiffman ML Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
6. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994 20 : 15 20.
7. Bedossa P Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24 : 289 93.
8. Imbert-Bismut F Ratziu V Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001 357 : 1069 75.
9. Myers RP Benhamou Y Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003 17 : 721 5.
10. Myers RP De Torres M Imbert-Bismut F, et al. Biochemical markers of fibrosis in patients with chronic hepatitis C: A comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci 2003 48 : 146 53.
11. Poynard T Imbert-Bismut F Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: Longitudinal validation in a randomized trial. J Viral Hepat 2002 9 : 128 33.
12. Poynard T McHutchison J Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003 38 : 481 92.
13. Rossi E Adams L Prins A, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003 49 : 450 4.
14. Thabut D Simon M Myers RP, et al. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 2003 37 : 1220 1 author reply 1221.
15. Myers RP Ratziu V Imbert-Bismut F, et al. Biochemical markers of liver fibrosis: A comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002 97 : 2419 25.
16. Halfon P Imbert-Bismut F Messous D, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002 1 : 3.
17. McGill DB Rakela J Zinsmeister AR, et al. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990 99 : 1396 400.
18. Tremolada F Casarin C Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992 16 : 273 81.
19. Di Bisceglie AM Goodman ZD Ishak KG, et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991 14 : 969 74.
20. Koretz RL Abbey H Coleman E, et al. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med 1993 119 : 110 5.
21. Wong JB McQuillan GM McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000 90 : 1562 9.
22. Yuen MF Cheng CC Lauder IJ, et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000 31 : 330 5.
23. McHutchison JG Gordon SC Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 : 1485 92.
24. Poynard T Marcellin P Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998 352 : 1426 32.
25. Zeuzem S Feinman SV Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000 343 : 1666 72.
26. Heathcote EJ Shiffman ML Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000 343 : 1673 80.
27. Lindsay KL Trepo C Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001 34 : 395 403.
28. Sobesky R Mathurin P Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. The Multivirc Group. Gastroenterology 1999 116 : 378 86.
29. Camma C Giunta M Andreone P, et al. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol 2001 34 : 593 602.
30. Imai Y Kasahara A Tanaka H, et al. Interferon therapy for aged patients with chronic hepatitis C: Improved survival in patients exhibiting a biochemical response. J Gastroenterol 2004 39 : 1069 77.
31. Ratziu V Dargere D Conti M, et al. Increased fibrotic response in the aging liver. Hepatology 2000 32:302A.